February 15, 2010 - New data released shows targeted radiotherapy, using real-time prostate tumor tracking during external beam radiation, enables the delivery of high doses of radiation, while reducing treatment-related side effects, including bowel urgency, rectal irritation and urinary irritation.

The study, which was presented at the 51st annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), November1-4,2009, was significant because radiation for prostate cancer is often delivered without real-time tracking, which can result in the morbidities due to unintended irradiation of healthy tissue. The tumor tracking technology works similar to the GPS system in cars and is installed in more than 90 medical centers nationwide.
 
The objective of the study was to investigate whether patient-reported quality of life after high-dose external beam intensity-modulated radiotherapy for prostate cancer can be improved by decreasing planning target volume margins while using real-time tumortracking.

In the study, patients underwent radiotherapy with nominal 3-mm margins and electromagnetic real-time tracking. Morbidity was assessed before and at the end of radiotherapy using Expanded Prostate Cancer IndexComposite (EPIC) questionnaires. Changes in scores were compared between the Assessing Impact of Margin Reduction(AIM) study cohort and the comparator PROST-QAcohort, treated with conventional margins.

The authors concluded that prostate cancer patients treated with reduced margins and tumor tracking had less radiotherapy- related morbidity than their counterparts treated with conventional margins. Highlycontoured intensity-modulated radiotherapy shows promise as a successful strategy for reducing morbidity in prostate cancer treatment.

Reference: Sandler, H, et al. Reduction in Patient-reported Acute Morbidity in Prostate Cancer Patients Treated With 81-Gy Intensity-modulated Radiotherapy Using Reduced Planning Target Volume Margins and Electromagnetic Tracking: Assessing the Impact of Margin Reduction Study.

 


Related Content

News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | Radiation Therapy

February 8, 2024 — RaySearch Laboratories AB announced that The Royal Marsden NHS Foundation Trust, a specialist cancer ...

Time February 08, 2024
arrow
News | Treatment Planning

February 2, 2024 — RaySearch Laboratories announced that the number of radiotherapy centers that have chosen RayStation ...

Time February 02, 2024
arrow
Feature | Radiation Oncology | By Melinda Taschetta-Millane

Over the past several years, technological advancements have driven the development of more precise and targeted ...

Time January 16, 2024
arrow
Feature | Artificial Intelligence

Coherent Market Insights has recently published a report, titled, Artificial Intelligence in Oncology Market, By ...

Time January 12, 2024
arrow
Videos | Radiation Oncology

In Part 2 of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory board ...

Time January 09, 2024
arrow
Subscribe Now